Can Creative Proteomics support unlisted natural product compounds?

Yes. Custom workflows for complex natural product mixtures, multi-component profiling, herbal extract characterization, and human-unique metabolite analysis.

How does natural product bioanalysis differ from single-compound small-molecule DMPK?

Natural product mixtures require multi-component analytical methods covering multiple structurally related analytes in a single run, with subtype-specific quantification, batch-to-batch consistency profiling, and human-unique metabolite characterization — rather than single-analyte LC-MS/MS methods.

Natural Products Library

Natural Products DMPK and Bioanalytical Services

Q: Why do ginsenosides require multi-component profiling rather than single-analyte quantification?

Ginsenosides exist as complex mixtures of multiple structurally related subtypes (Rb1, Rb2, Rc, Rd, Rg1, Re, etc.) with distinct pharmacological activities. Total ginsenoside concentration without subtype distribution data produces an incomplete analytical profile — the same total concentration with different subtype ratios has different biological effects.

Ginsenosides represent a modality unique in this library: they are not single small molecules, not biologics, but complex natural product mixtures — multiple structurally related dammarane-type saponin subtypes (Rb1, Rb2, Rc, Rd, Rg1, Re, etc.) coexisting in a single analytical sample. Total ginsenoside concentration without subtype distribution data produces an incomplete profile — the same total concentration with different subtype ratios has different biological activity. Their bioanalysis requires multi-component profiling, human-unique metabolite characterization, and a research-use-only (RUO) framework that distinguishes naturally derived compounds from synthetic pharmaceutical standards.

Creative Proteomics provides ginsenoside multi-component profiling, subtype-specific quantification, human-unique metabolite analysis, and custom natural product bioanalysis panel development.

Browse Drug Index Request Custom Method Support

Complex Mixture, Not Single AnalyteGinsenosides exist as multiple structurally related subtypes — requires multi-component profiling, not single-analyte quantification.

Human-Unique Metabolite ProfilingHuman-specific ginsenoside metabolites require RUO research-use characterization distinct from synthetic drug bioanalysis.

Natural Products ModalityFirst Natural Products entry — distinct from both small molecules and biologics in analytical approach.

Ginsenoside Analytical Challenges DMPK Strategy Map

⚡

Complex Mixture ProfilingMultiple ginsenoside subtypes (Rb1, Rb2, Rc, Rd, Rg1, Re, etc.) require multi-analyte LC-MS/MS methods, not single-analyte quantification.

🧬

Subtype-Specific QuantificationEach ginsenoside subtype has distinct pharmacological activity. Total concentration without subtype distribution is an incomplete analytical result.

📊

Human-Unique (RUO) CharacterizationHuman-specific ginsenoside metabolites require research-use-only metabolite identification — differentiated from synthetic pharmaceutical metabolites.

🔬

Batch-to-Batch ConsistencyNatural product composition varies by source, extraction method, and processing — batch-to-batch profiling is an analytical requirement for therapeutic consistency.

Natural product multi-component bioanalysis.Creative Proteomics approaches ginsenosides as complex mixtures requiring subtype-resolved quantification and human-unique metabolite identification — because total ginsenoside concentration, without subtype and metabolite distribution data, is an incomplete analytical profile.

Natural Product Drug Index

Find the Natural Product Compound Behind the Study

Natural product bioanalysis requires multi-component profiling rather than single-analyte quantification. Ginsenosides exist as complex mixtures of structurally related subtypes — each with distinct pharmacological activity. The panel is intentionally concise so detailed compound monographs can be added separately.

A–Z anchors

Filter by study tagsSelect a field to reveal its tags.

1 entry · Page 1 of 1

Analytical Pain Points

What Drives Assay Failure in Natural Product Studies?

Ginsenoside bioanalysis fails when treated as a single-analyte target. Total ginsenoside concentration without subtype distribution and human-unique metabolite data produces an incomplete analytical profile — concentration without composition is not a meaningful result for natural product mixtures.

Complex Mixture Requires Multi-Component Quantification

Ginsenosides exist as multiple structurally related subtypes (Rb1, Rb2, Rc, Rd, Rg1, Re, etc.). Total ginsenoside concentration masks subtype distribution — the same total with different subtype ratios has different biological activity.

Our responseMulti-analyte LC-MS/MS method covering all major ginsenoside subtypes in a single run with subtype-specific calibration.

Phase I & II Metabolite Characterization →

Human-Unique Metabolite Identification

Ginsenosides undergo species-specific metabolism. Human-unique metabolites differ from rodent or in vitro metabolism data. RUO human-metabolite characterization requires distinct reference standards and analytical conditions.

Our responseHuman-specific ginsenoside metabolite identification with RUO framework — not synthetic pharmaceutical metabolite compliance workflows.

Metabolite Identification →

Single-Analyte Method Misses the Mixture

A validated single-analyte LC-MS/MS method for ginsenoside Rb1, for example, produces zero data on Rg1, Re, or other pharmacologically active subtypes. The mixture requires multi-analyte coverage from method inception.

Our responseMulti-component method design from the start — all relevant subtypes included in calibration and validation, not added as an afterthought.

Custom LC-MS/MS Method Development →

Batch-to-Batch Compositional Variability

Ginsenoside composition varies by ginseng source, extraction method, and processing conditions. A method validated on one batch may not transfer to another without compositional adjustment.

Our responseBatch-to-batch compositional profiling with subtype distribution QC criteria — ensuring analytical method validity across production batches.

Custom LC-MS/MS Method Development →

RUO vs Pharmaceutical Bioanalysis Standards

Natural product bioanalysis operates under a research-use-only (RUO) framework — distinct from pharmaceutical GLP/GCP-regulated bioanalysis. Method expectations, validation scope, and data interpretation differ.

Our responseRUO-appropriate method development with natural-product-specific validation criteria — fit-for-purpose rather than pharmaceutical compliance.

Custom Panels →

Focused Service Paths

Four Practical Routes for Natural Product Studies

Natural product workflows should be selected by analytical scope: multi-component ginsenoside profiling for subtype-resolved quantification; human-unique metabolite characterization; batch-to-batch compositional consistency; or custom natural product bioanalysis panels.

Multi-Component Ginsenoside Profiling

Subtype-resolved quantification of multiple ginsenoside analogs (Rb1, Rb2, Rc, Rd, Rg1, Re, etc.) in a single multi-analyte LC-MS/MS method.

All major subtypes in one chromatographic run
Subtype-specific calibration and MRM
Total + subtype distribution reporting

Phase I & II Metabolite Characterization →

Human-Unique Metabolite ID (RUO)

Species-specific ginsenoside metabolite characterization — identifying human-unique metabolites under RUO framework.

Human-specific metabolite profiling
RUO metabolite reference standard work
Distinct from pharmaceutical GLP MetID

Metabolite Identification →

Batch-to-Batch Compositional Analysis

Source-to-source and batch-to-batch ginsenoside compositional profiling for quality and method transferability.

Subtype distribution QC criteria per batch
Source-specific compositional baselines
Method transferability assessment across batches

Custom LC-MS/MS Method Development →

Custom Natural Product Bioanalysis Panel

RUO-appropriate multi-component natural product bioanalysis — subtype profiling, metabolite ID, and batch composition in one study.

Multi-component quantification method
Human-unique metabolite characterization
Batch-to-batch QC integration

Custom Multi-Analyte Drug Panels →

Project Inquiry

Need Natural Product or Ginsenoside Bioanalysis?

If your study requires multi-component ginsenoside profiling, human-unique metabolite identification, or batch-to-batch composition analysis — Creative Proteomics builds RUO-appropriate natural product workflows.

Creative Proteomics determines whether the analytical endpoint is total concentration, subtype distribution, or metabolite identification — then selects multi-analyte or single-analyte methods accordingly.

Target natural product

Multi-component or single-analyte

Subtype coverage

Human-unique MetID needed

Batch-to-batch comparison

RUO framework level

Natural Products DMPK and Bioanalytical Services

Find the Natural Product Compound Behind the Study

What Drives Assay Failure in Natural Product Studies?

Complex Mixture Requires Multi-Component Quantification

Human-Unique Metabolite Identification

Single-Analyte Method Misses the Mixture

Batch-to-Batch Compositional Variability

RUO vs Pharmaceutical Bioanalysis Standards

Four Practical Routes for Natural Product Studies

Multi-Component Ginsenoside Profiling

Human-Unique Metabolite ID (RUO)

Batch-to-Batch Compositional Analysis

Custom Natural Product Bioanalysis Panel

Need Natural Product or Ginsenoside Bioanalysis?

Ready to Quantify Your Lead Compound or Metabolite?